Publication

Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer

Gijtenbeek, R. G. P., Damhuis, R. A. M., Groen, H. J. M., van der Wekken, A. J. & van Geffen, W. H., 22-May-2020, In : Clinical lung cancer. 6, p. e647-e653 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non–small-cell Lung Cancer

    Proof, 295 KB, PDF document

    Request copy

DOI

Most trials regarding tyrosine kinase inhibitors in patients with advanced epidermal growth factor receptor-mutated non–small-cell lung cancer comprised selected series from Asian populations. We found that Western European patients with epidermal growth factor receptor-mutated non–small-cell lung cancer who received first-line treatment with regular tyrosine kinase inhibitors have a median overall survival of 20.2 months in our large nationwide real-world cohort. In patients with brain metastasis, erlotinib showed superior results compared with gefitinib and was similar to afatinib.

Original languageEnglish
Pages (from-to)e647-e653
Number of pages7
JournalClinical lung cancer
Issue number6
Publication statusE-pub ahead of print - 22-May-2020

ID: 129133884